The Monday Brief — Week of Jun 26, 2026

The FDA approved Skinvive by Juvéderm for horizontal neck lines and "tech neck"—a direct answer to a high-demand, high-margin indication that medspas have been chasing off-label. Restylane Contour now has FDA clearance for temple hollowing, and RHA Dynamic Volume is approved for midface augmentation and age-related volume loss. These aren't niche approvals; they're high-visibility indications that patients are already asking for. The strategic play: stock these early, train your team on technique and patient selection, and position them as premium offerings. Each approval expands your menu and justifies price points—but only if you move before competitors saturate the market.

AbbVie has filed three material events in three months (April 29, May 12, June 22)—all tied to Botox/Juvéderm pricing, rebate structures, and Allē loyalty program changes. These aren't routine updates; they signal active reshuffling of the economics that drive your cost of goods and patient acquisition. Repeated filings suggest volatility in the rebate and pricing landscape. Action item: Review your current Allē participation terms and rebate tiers. If AbbVie is restructuring incentives, your margin assumptions may shift. Don't assume last quarter's rebate is next quarter's rebate. Lock in volume commitments or renegotiate terms now if you have leverage.

Evolus has filed two material events (March 13, May 4, June 12) centered on Jeuveau and Evolus Rewards—a direct-to-medspa loyalty play designed to undercut AbbVie's Allē dominance. Evolus markets aggressively to independent practices, offering rebates and incentives that can move volume. This is where price wars start: when a smaller competitor offers better terms to medspas than the category leader. Watch this: If Evolus gains traction with your peers, AbbVie will likely respond with counter-offers. Use this competition to your advantage—shop your volume, ask for better terms, and don't lock into long-term commitments until the dust settles.

InMode received an unsolicited acquisition proposal on June 17 at $16.20 per share from a CEO-linked group. The company confirmed receipt, and the stock surged. Separately, analysts have downgraded the stock, citing market headwinds. For medspa owners who use InMode devices (radiofrequency, microneedling, body contouring), this matters: M&A uncertainty can affect service, support, and software updates. What to monitor: If InMode is acquired, will the new owner maintain the same pricing, support model, and product roadmap? If the deal falls through, will the stock volatility affect the company's R&D and customer focus? Don't panic, but stay informed on the deal timeline.

Allergan Aesthetics received Health Canada approval for Boey (trenibotulinumtoxinE)—a rapid-onset, short-duration neuromodulator for glabellar lines. It's the first of its kind in Canada. U.S. FDA approval status is not yet confirmed in this period's reporting. Boey could be a game-changer if it hits the U.S. market: faster onset and shorter duration mean more frequent treatments and higher annual revenue per patient. For now: Monitor FDA communications and industry conferences for U.S. approval signals. If Boey lands in the U.S., it will compete directly with Botox and Jeuveau on speed and duration—not price. Early adopters will capture the premium market.

The FDA and state authorities are actively prosecuting unlicensed injectors and counterfeit injectable cases. Recent enforcement actions include a Port St. Lucie medspa owner sentenced to 45 years for botched cosmetic surgery, a Southlake spa accused of using illegal off-brand Botox, and a Stoughton medspa owner admitting to injecting clients with fake Botox. These aren't isolated incidents—they're part of a sustained enforcement push. The takeaway: Verify your supply chain, audit your staff credentials, and document every injectable lot number and expiration date. Compliance is not optional; it's existential. One counterfeit batch or unlicensed injector can shut you down and expose you to criminal liability.